Longitude Capital

The firm is run by co-founders Patrick Enright and Juliet Tammenoms Bakker, who serve as managing directors and co-head the investment committee. Both have been investing in life sciences since before founding Longitude in 2006 — Enright formerly led healthcare investing at Pequot Ventures, and Tammenoms Bakker covered medical devices at ABN AMRO and later joined Pequot as a managing director. The partnership operates a flat decision-making structure, with senior principals and principals sourcing within their clinical or device specialties.

Longitude relies on a physician-and-operator network: the investment team is built around professionals with MDs, PhDs, or operating experience inside pharmaceutical and medtech companies. The firm also maintains relationships with academic tech-transfer offices at major research universities, particularly on the West Coast. Because Longitude does not compete in software or industrials, it often gets the first call from scientific founders and venture-creation firms seeking a dedicated healthcare investor.

Longitude avoids healthcare areas where the firm believes its specialization provides no advantage. It does not invest in capital-equipment-dependent medtech, late-stage single-asset plays without a novel mechanism of action, or healthcare IT companies that are predominantly workflow-software businesses rather than clinical decision-support tools. The firm also avoids consumer wellness and direct-to-consumer diagnostics, staying strictly within regulated biomedical products and services.

Longitude syndicates regularly but prefers to lead or co-lead rounds in its core biotech and device investments, using lead-investor status to secure board representation. The firm co-invests with crossover funds (for pre-IPO biotechs), traditional venture firms, and, in services, with growth equity investors. The partnership evaluates each syndicate on whether the assembled investor group can support the company through a full clinical and regulatory cycle, not just the current financing round.